Context Therapeutics (NASDAQ:CNTX – Get Free Report) is projected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Context Therapeutics to post earnings of ($0.09) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, analysts expect Context Therapeutics to post ($0.45) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.
Context Therapeutics Stock Performance
Shares of CNTX opened at $0.23 on Wednesday. Context Therapeutics has a 52 week low of $0.22 and a 52 week high of $3.62. The firm has a market cap of $21.56 million, a P/E ratio of -0.49 and a beta of 1.71. The firm’s 50-day simple moving average is $0.35 and its 200 day simple moving average is $1.47.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on CNTX shares. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Lifesci Capital lowered Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Zacks Research cut Context Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. Weiss Ratings upgraded Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 15th. Finally, Wall Street Zen downgraded Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.17.
Read Our Latest Research Report on Context Therapeutics
Context Therapeutics Company Profile
Context Therapeutics Inc (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens.
Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.
Further Reading
- Five stocks we like better than Context Therapeutics
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
